Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

  • Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19 vaccine reduced the risk of transmission to household members compared to placebo participants.
  • Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax Technologies Corp's DVAX CpG 1018 advanced adjuvant and aluminum hydroxide (alum). 
  • The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 compared to households where the infected household member was not vaccinated. 
  • Related: China-Based COVID-19 Shot Neutralizes Omicron Subvariants.
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one COVID-19 case; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • No cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019. 
  • Clover is working towards completing regulatory submissions in China, Europe, and the World Health Organization for SCB-2019 by the end of 2022.
  • Price Action: DVAX shares closed at $11.88 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!